|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 1990s, interferons alpha-2 were used in the treatment of HCV and in the next decade HCV therapy was based on pegylated interferon alpha-2 in combination with ribavirin.
|
30685524 |
2019 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China.
|
26470765 |
2016 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
|
17875005 |
2007 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The population pharmacokinetics of ribavirin were assessed in patients with chronic hepatitis C virus (HCV) infection treated with interferon alpha-2b and ribavirin in four clinical efficacy studies.
|
11034261 |
2000 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the use of latent IFNα2b can be considered again as an option for treatment of HCV infection in combination with direct acting antivirals rather than alone with improved safety profile.
|
31350425 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients.
|
23684903 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
|
16761995 |
2006 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
|
9310930 |
1997 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
ADJ higher doses of RBV based on its early pharmacokinetics-based RBV do not improve SVR rates in HCV GT4 treated in combination with peg-IFN alpha-2-a versus STD therapy.
|
29135370 |
2017 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to compare the efficacy and tolerability of pegylated interferon (PEG-IFN) plus ribavirin (RIB) and PEG-IFN monotherapy after unsuccessful initial therapy with interferon-α2b (IFN) plus RIB after recurrent post-transplantation hepatitis C.
|
20438578 |
2011 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 67-year-old man with hepatitis C virus infection and histological features of chronic active hepatitis was treated with human recombinant interferon alpha-2b.
|
10535477 |
1999 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon alpha-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1.
|
17406822 |
2007 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels.
|
31602234 |
2019 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the demonstration of HCV RNA in the cryoprecipitate of patients with essential mixed cryoglobulinemia and a beneficial response to treatment with interferon alpha-2b also suggest a role for HCV in the pathogenesis of these clinical syndromes.
|
7810528 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed stored pretreatment sera retrospectively from 22 patients with HCV-1b infection who had received interferon alpha-2b (IFNalpha-2b) as part of a controlled trial.
|
10421401 |
1999 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 71 treatment-naive HCV RNA-positive patients with biopsy-confirmed chronic hepatitis, with genotype 2b or 3a, viral load < or = 3 million copies per ml and no cirrhosis were randomized to receive either standard interferon therapy (3 MIU interferon-alpha-2a thrice weekly) for 26 weeks or 6 MIU interferon-alpha-2a daily for 4 weeks (induction group) followed by the standard dose (3 MIU thrice weekly) for 22 weeks.
|
11916198 |
2002 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon alpha-2a (n = 20) or alpha-2b (n = 22) combined with oral ribavirin for 48 weeks.
|
18657036 |
2008 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.
|
25071908 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of the present analysis is to describe the change in neutrophil count resulting from peglated interferon alpha 2-a (PEG-IFN α-2a) therapy in HCV-infected patients.
|
29872876 |
2018 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
At the end of week 48, HCV RNA was undetectable in 14 of 54 patients (25.9%) receiving pegylated interferon-alpha-2a and in 15 of 54 patients (27.7%) receiving pegylated interferon-alpha-2b.
|
18416586 |
2008 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
|
7636506 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-naive patients with chronic HCV infection (n = 187) were randomly chosen to receive 15 microg CIFN or 9 microg or 3 MU IFN-alpha-2a subcutaneously, three times a week for 24 weeks, followed by a 24 week observation period.
|
11106097 |
2000 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1.
|
22799464 |
2012 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study sought to confirm the association between HCV and the Delta 32 mutation of the CCR5 gene and to correlate it with the response to therapy with interferon-alpha-2a and ribavirin.
|
12865070 |
2003 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to compare the efficacy of 6 and 12 months of combination therapy with interferon alpha-2b and ribavirin in patients with bleeding disorders and chronic HCV.
|
11952848 |
2002 |